Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys (Q31882710)

4 July 2017

title

Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys (English)

1 reference

4 July 2017

1 reference

Hadj Tahar A

1 reference

4 July 2017

Ekesbo A

1 reference

4 July 2017

Grégoire L

1 reference

4 July 2017

Bangassoro E

1 reference

4 July 2017

Svensson KA

1 reference

4 July 2017

Tedroff J

1 reference

4 July 2017

Bédard PJ

1 reference

4 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

European Journal of Pharmacology

4 July 2017

published in

1 reference

4 July 2017

volume

412

1 reference

4 July 2017

1 reference

4 July 2017

page(s)

247-254

1 reference

Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia?

4 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900737-3

A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900737-3

(−)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinsonʼs disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900737-3

Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900737-3

Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900737-3

Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900737-3

Potential therapeutic use of the selective dopamine D 1 receptor agonist, A-86929: An acute study in parkinsonian levodopa-primed monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900737-3

D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900737-3

Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900737-3

Synthesis of [11C-methyl]-(−)-OSU6162, its regional brain distribution and some pharmacological effects of (−)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900737-3

The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900737-3

Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900737-3

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900737-3

Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900737-3

Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900737-3

10.1016/S0014-2999(01)00737-3

7 January 2021

Identifiers

DOI

1 reference

4 July 2017

1 reference